New App for Prostate Ultrasound System Announced

The urologist can also use the MRI-identified lesions during the total biopsy procedure.

The FusionVu application was developed by Exact Imaging and runs on the company's ExactVu platform. According to Exact Imaging this provides the urologist with a total urological solution that can be upgraded, and scaled up. The system is based on standard urological workflows, and does not need any additional hardware or radiological software to run. FusionVu is intended for patients with exclusive anterior lesions, or those with previous negative biopsies.

Exact Imaging's ExactVu micro-ultrasound platform works at 29 MHz, and has received the European Union (CE Mark), US FDA 510(k) approval, and the Health Canada license. The system can be used for systematic biopsy protocols, and can visualize areas of interest in the prostate and target biopsies in those areas.

President and CEO of Exact Imaging, Randy AuCoin, said, "At least 70% of prostate cancer is located in the peripheral zone, which is exquisitely visualized and targetable with the 70 micron resolution of the ExactVu micro-ultrasound system. Our evidence-based PRI-MUS protocol is easily applied to help urologists identify and characterize regions and then to target those suspicious regions."